Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s Why

Mesoblast Limited (NASDAQ:MESO) gapped down before the market opened on Wednesday . The stock had previously closed at $18.04, but opened at $17.07. Mesoblast shares last traded at $17.65, with a volume of 202,085 shares traded.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MESO shares. Piper Sandler boosted their price target on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, December 19th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.50.

Mesoblast Stock Up 2.5 %

The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The business’s fifty day moving average is $14.51 and its 200-day moving average is $10.06.

Institutional Trading of Mesoblast

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new position in shares of Mesoblast in the 4th quarter worth $30,000. Signaturefd LLC lifted its stake in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Mesoblast during the 4th quarter worth about $134,000. Finally, Ballentine Partners LLC acquired a new stake in Mesoblast during the 4th quarter worth approximately $222,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.